Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice

AIM: Combined therapy of EGFR TKI and VEGFR TKI may produce a greater therapeutic benefit and overcome EGFR TKI-induced resistance. However, a previous study shows that a combination of EGFR TKI erlotinib (ER) with VEGFR TKI sunitinib (SU) did not improve the overall survival in patients with non-sm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: Li, Jing-yun, Ren, Yu-peng, Yuan, Yin, Ji, Shuang-min, Zhou, Shu-pei, Wang, Li-jie, Mou, Zhen-zhen, Li, Liang, Lu, Wei, Zhou, Tian-yan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933764/
https://ncbi.nlm.nih.gov/pubmed/27180983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.55
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados